Patents by Inventor Stewart D. Lyman

Stewart D. Lyman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods to Determine the Presence of an Antibody that Binds Modified Human Thymic Stromal Lymphopoietin (TSLP)
    Publication number: 20210102955
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: September 14, 2020
    Publication date: April 8, 2021
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • METHODS TO DETERMINE THE PRESENCE OF AN ANTIBODY THAT BINDS MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN (TSLP)
    Publication number: 20160377630
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 29, 2016
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Antibodies that inhibit TSLP activity
    Patent number: 9346870
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: September 16, 2014
    Date of Patent: May 24, 2016
    Assignee: IMMUNEX CORPORATION
    Inventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Jacob
  • Modified Human Thymic Stromal Lymphopoietin
    Publication number: 20150252089
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Nucleic acids encoding modified human thymic stromal lymphopoietin
    Patent number: 9045558
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: June 2, 2015
    Assignee: IMMUNEX CORPORATION
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Antibodies That Inhibit TSLP Activity
    Publication number: 20150005226
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: September 16, 2014
    Publication date: January 1, 2015
    Inventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Jacob
  • Modified Human Thymic Stromal Lymphopoietin
    Publication number: 20140093956
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: December 3, 2013
    Publication date: April 3, 2014
    Applicant: IMMUNEX CORPORATION
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Modified human thymic stromal lymphopoietin
    Patent number: 8598318
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: December 3, 2013
    Assignee: Amgen Inc.
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond Paxton
  • Antibodies That Inhibit TSLP Activity
    Publication number: 20130225490
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: May 6, 2013
    Publication date: August 29, 2013
    Applicant: IMMUNEX CORPORATION
    Inventors: John Ernest Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
  • Antibodies that inhibit TSLP activity
    Patent number: 8444979
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: May 21, 2013
    Assignee: Immunex Corporation
    Inventors: John E Sims, Stewart D Lyman, Hilary J McKenna, Allison P Armstrong
  • ANTIBODIES THAT INHIBIT TSLP ACTIVITY
    Publication number: 20120014961
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: September 23, 2011
    Publication date: January 19, 2012
    Inventors: John E SIMS, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
  • MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
    Publication number: 20110230637
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: June 1, 2011
    Publication date: September 22, 2011
    Applicant: IMMUNEX CORPORATION
    Inventors: Stewart D. LYMAN, Kirk P. VAN NESS, Raymond J. PAXTON
  • Nucleic acid encoding modified human thymic stromal lymphopoietin
    Patent number: 7973151
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: July 5, 2011
    Assignee: Amgen Inc.
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • METHODS OF USING FLT3-LIGAND IN THE TREATMENT OF CANCER
    Publication number: 20110053863
    Abstract: Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.
    Type: Application
    Filed: May 6, 2009
    Publication date: March 3, 2011
    Applicant: CELLDEX THERAPEUTICS INC.
    Inventors: Stewart D. LYMAN, M. Patricia BECKMANN
  • ANTIBODIES THAT INHIBIT TSLP ACTIVITY
    Publication number: 20100266601
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: June 23, 2010
    Publication date: October 21, 2010
    Applicant: IMMUNEX CORPORATION
    Inventors: John E. SIMS, Stewart D. LYMAN, Hilary J. MCKENNA, Allison P. ARMSTRONG
  • Antibodies that inhibit TSLP activity
    Patent number: 7786271
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: July 28, 2008
    Date of Patent: August 31, 2010
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong
  • MODIFIED HUMAN THYMIC STROMAL LYMPHOPOIETIN
    Publication number: 20100167393
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: March 12, 2010
    Publication date: July 1, 2010
    Applicant: IMMUNEX CORPORATION
    Inventors: Stewart D. LYMAN, Kirk P. VAN NESS, Raymond J. PAXTON
  • Modified human thymic stromal lymphopoietin
    Patent number: 7709217
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Grant
    Filed: October 30, 2007
    Date of Patent: May 4, 2010
    Assignee: Immunex Corporation
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • Dendritic cell stimulatory factor
    Publication number: 20090075886
    Abstract: Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants.
    Type: Application
    Filed: August 7, 2008
    Publication date: March 19, 2009
    Inventors: Kenneth BRASEL, Stewart D. Lyman, Eugene Maraskovsky, Hilary R. McKenna, David H. Lynch, Charles R. Maliszewski
  • Antibodies that inhibit TSLP activity
    Publication number: 20090017034
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: July 28, 2008
    Publication date: January 15, 2009
    Applicant: IMMUNEX Corporation
    Inventors: John E. Sims, Stewart D. Lyman, Hilary J. McKenna, Allison P. Armstrong